INOVIQ Limited announced that a significant milestone had been reached in its exosome-based therapeutic programme, with laboratory studies confirming the treatment’s potent activity against two aggressive cancer types. The preclinical candidate, utilising CAR-NK-derived extracellular vesicles (EVs), was shown to eliminate 88% of triple-negative breast cancer (TNBC) and non-small-cell lung cancer (NSCLC) cells within 96 hours.
The platform employed a proprietary manufacturing method, EXO-ACE™, to engineer and purify these cancer-targeting vesicles. Unlike traditional cell therapies, the approach had been designed to enable standardised, scalable production of “off-the-shelf” treatments, eliminating the need for individual patient customisation.
“These results have validated the potential of our exosome therapeutic platform to deliver transformative, accessible treatments,” said Professor Greg Rice, Chief Scientific Officer at INOVIQ. “Compared to existing CAR-T therapies, our method offers meaningful advantages in cost, safety and effectiveness, with the versatility to address multiple solid tumour types.”
INOVIQ’s innovation involved using immune-cell derived particles to selectively target and destroy tumour cells. Independent experiments confirmed nearly 88% cell mortality in both TNBC and NSCLC cultures, far surpassing control treatments.
The therapy was now set to enter animal testing, representing the next critical phase prior to clinical trials in humans. Success in these models could lay the foundation for a faster, safer alternative to current immunotherapies.
David Williams, Chairman of INOVIQ, commented, “These findings bring us another step closer to providing life-changing therapeutic solutions for people living with cancer.”
INOVIQ’s exosome technology originated from its commitment to redefining cancer diagnostics and treatment. The company continues to pursue advancements in oncology through scientific rigour and strategic development of novel exosome-based applications.
